Cargando…
Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
Migraine affects the daily life of millions of people around the world. The most well-known disabling symptom associated with this illness is the intense headache. Nowadays, there are treatments that can diminish the level of pain. OnabotulinumtoxinA (BoNT-A) has become a very popular medication for...
Autores principales: | Parrales Bravo, Franklin, Del Barrio García, Alberto A., Gallego, María Mercedes, Gago Veiga, Ana Beatriz, Ruiz, Marina, Guerrero Peral, Angel, Ayala, José L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401533/ https://www.ncbi.nlm.nih.gov/pubmed/30886915 http://dx.doi.org/10.1016/j.heliyon.2018.e01043 |
Ejemplares similares
-
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2021) -
OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
por: Pedraza, María Isabel, et al.
Publicado: (2015) -
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
por: Moreno-Mayordomo, R., et al.
Publicado: (2019) -
Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)